ClinicalTrials.gg
CompletedNCT00032955Updated Jan 12, 2017

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

A Phase 3 interventional study of Buprenorphine/naloxone in Heroin Dependence, Morphine Dependence and Substance Withdrawal Syndrome, sponsored by University of California, Los Angeles. Completed at 6 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by University of California, Los Angeles · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
163
Ages
15 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.

Read the detailed description

Patients randomized to the BUP/NX arm will receive daily doses for 13 days with sublingual administration of 2 mg buprenorphine/0.5 mg naloxone tablet(s) and/or an 8 mg buprenorphine/2.0 mg naloxone tablet(s). The starting dose on day 1 is 4 mg/1 mg BUP/NX with an additional 4 mg/1 mg, if needed, escalating in a step-wise manner to 16 mg/4 mg BUP/NX on day 3 and tapering to 2 mg/ 0.5 mg BUP/NX by days 12 to 13. Patients randomized to the clonidine arm will receive oral clonidine (0.05 to 0.1 mg depending upon weight) every 4 to 6 hours for 24 hours not to exceed 0.6 mg total on day 1. On day 2, a clonidine transdermal patch will be applied (0.1 mg/day/7-day patch with number of patches adjusted by weight). Oral clonidine will continue to be given on the second day of detoxification and increased to 0.2 mg every 6 hours or 0.1 mg every 3 hours not to exceed 0.8 mg over 24 hours. Patches will be worn all 13 days of detoxification. The dose of clonidine will be adjusted according to the proposed detoxification schedule, patient's weight, tolerance, and systolic blood pressure. Patients will receive counseling according to procedures in existence at each CTP throughout the study. Self-help detoxification handbooks will be distributed to all study participants.

02

Conditions studied

  • Heroin Dependence
  • Morphine Dependence
  • Substance Withdrawal Syndrome

Keywords

  • opiate addiction
  • morphine addiction
03

In context

Heroin Dependence

90 studies on the registry are indexed under Heroin Dependence; 1 is open to participants now.

This study's enrollment of 163 is above the median of 87 across 57 interventional studies indexed under Heroin Dependence.

Browse Heroin Dependence studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 195 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Treatment-seeking males and non-pregnant and non-lactating females, 15 years and older, who fulfill criteria for opiate dependence, report experiencing symptoms of opiate withdrawal, are currently physically dependent on opioids, and are need of medical assistance for opioid withdrawal.
  2. Systolic blood pressure > or = 100mm Hg, and pulse > or = 56 bpm.
  3. Good general health or, in case of a medical/psychiatric condition needing ongoing treatment, under the care of a physician willing to continue patient's medical management and cooperate with the study physicians.
  4. Agreeable to and capable of signing the approved by an institutional review board and, if under the age of 18 (excluding emancipated minors), assent and concurrent consent from a parent or legal guardian.
  5. Use of one of the following acceptable methods of by female patients of :

    1. oral contraceptives
    2. barrier (diaphragm or cervical cap) with spermicide or condom
    3. intrauterine progesterone contraceptive system
    4. levonorgestrel implant
    5. medroxyprogesterone acetate contraceptive injection
    6. complete abstinence from sexual intercourse

Exclusion criteria

Exclusion Criteria:

  1. Medical condition that would make participation, in the opinion of the study physician, medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease);
  2. abnormalities in .
  3. Known allergy or sensitivity to buprenorphine, naloxone, or clonidine.
  4. Receiving beta-blockers, calcium channel blockers, tricyclics, digitalis and other medications which may interact adversely with clonidine.
  5. Acute severe psychiatric condition in need of immediate treatment, or imminent suicide risk.
  6. Dependence on alcohol, benzodiazepines or other depressants, or stimulants, and requiring immediate medical attention.
  7. Participation in an drug study, including buprenorphine, within the past 30 days.
  8. Methadone or LAAM maintenance or detoxification within 30 days of enrollment.
  9. Pending legal action that could prohibit or interfere with participation.
  10. Unable to remain in area for duration of active phase of treatment.
  11. Females that are pregnant, lactating, or planning to become pregnant.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
None (open label)
Enrollment
163 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Drug use

  2. Degree of drug craving

  3. Adverse events

  4. Drug craving

  5. Decreased frequency of HIV related behavior

  6. Adverse effect measures

07

Study locations

6 sites
  • Betty Ford Center
    Rancho Mirage, California 92270, United States
  • The Center For Drug-Free Living
    Orlando, Florida 32801, United States
  • Operation PAR, Inc.
    Pinellas Park, Florida 33781, United States
  • Self Help Addiction Rehabilitation (SHAR), Inc.
    Detroit, Michigan 48208, United States
  • Phoenix House
    New York, New York 10023, United States
  • Maryhaven, Inc.
    Columbus, Ohio 43207, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001, a primary completion of Aug 2002 and a completion of Aug 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2002
First posted
Apr 8, 2002
Start
Feb 2001
Primary completionActual
Aug 2002
CompletionActual
Aug 2002
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00032955
First posted
Apr 8, 2002
Start date
Feb 2001
Primary completion
Aug 2002
Completion
Aug 2002
Last update
Jan 12, 2017

Study contacts

Walter Ling, M.D.
principal investigator · Los Angeles Treatment Research Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Buprenorphine · Naloxone

Start the discussion